Close

Now Playing:

Wednesday brought an end to the long-awaited deal between French pharmaceutical company Sanofi-Aventis and the U.S. biotech firm Genzyme. Sanofi will buy Genzyme for at least $20.1 billion. But the number could go higher if Genzym's drugs-in-development succeed when they go to market, as Eve Troeh explains.